ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Multiomic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
purposeGastrointestinal stromal tumor (GIST) is a genomically driven neoplasm with a genetic profile that determines the clinical course of the disease. However, currently available molecular data are limited because of the rarity of the disease and do not fully capture GIST clinical and biological heterogeneity. EXPERIMENTAL
designTo gain deeper insights into the molecular landscape of GIST, we performed a comprehensive multiomic analysis (targeted panel, whole-exome sequencing, and whole transcriptomics) in a large real-world, multicenter cohort including 1,427 cases. Pathologic review was undertaken in KIT/PDGFRA wild-type (WT) cases. Molecular findings were correlated with clinical data and insurance claims outcomes.
resultsThere is a complex spectrum of multilayered genetic events that converge in 3 GIST molecular subgroups: KIT-mutant, PDGFRA-mutant, and KIT/PDGFRA-WT. These alterations can be captured only by using next-generation sequencing technologies and are associated with clinical features, biological aggressiveness, and patient outcomes. Mutations in alternative genes, whether actionable or not, are seldom present and unlikely to contribute to tumor progression. By contrast, the cooperative effect of novel somatic copy-number alterations may be required for GIST evolution and progression, in addition to the core set of events involved in the current cytogenetic model of tumorigenesis.
conclusionsThis molecular landscape provides a broader molecular understanding of GIST and supports a widespread use of genetic profiling for patients' clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.